Symphogen goes solo after Merck KGaA returns rights to cancer antibody
This article was originally published in Scrip
Executive Summary
Merck KGaA has returned a Phase IIb immune-oncology compound back to its originator company Symphogen after a reassessment of its pipeline, but Symphogen is "pleased" with the turn of events.